LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 38

Search options

  1. Article ; Online: The Gut Microbiome: A Primer for the Clinician.

    Aroniadis, Olga C / Grinspan, Ari M

    The American journal of gastroenterology

    2023  Volume 119, Issue 1S, Page(s) S2–S6

    MeSH term(s) Humans ; Gastrointestinal Microbiome
    Language English
    Publishing date 2023-12-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 390122-1
    ISSN 1572-0241 ; 0002-9270
    ISSN (online) 1572-0241
    ISSN 0002-9270
    DOI 10.14309/ajg.0000000000002583
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Medical Cannabis Use Patterns and Adverse Effects in Inflammatory Bowel Disease.

    Greywoode, Ruby / Cunningham, Chinazo / Hollins, Maegan / Aroniadis, Olga

    Journal of clinical gastroenterology

    2023  Volume 57, Issue 8, Page(s) 824–829

    Abstract: Goals: To investigate medical cannabis (MC) use patterns and adverse effects in patients with inflammatory bowel disease (IBD).: Background: MC is now legal in many states. Although previous studies suggest improvement in disease activity among IBD ... ...

    Abstract Goals: To investigate medical cannabis (MC) use patterns and adverse effects in patients with inflammatory bowel disease (IBD).
    Background: MC is now legal in many states. Although previous studies suggest improvement in disease activity among IBD patients using MC, use patterns and adverse effects are unclear.
    Study: A cross-sectional anonymous survey was conducted (October 23, 2020 to January 24, 2021) among patients accessing MC dispensaries in New York and Minnesota. Eligibility criteria: age 18 years or older, selfreported IBD diagnosis, MC dispensary purchase. Survey questions included IBD characteristics, MC and healthcare utilization, and MC effects/adverse events. Participant characteristics were analyzed with descriptive statistics. Utilization patterns and symptoms before and after MC use were compared using the Stuart Maxwell test.
    Results: Of 236 respondents, overall IBD disease activity was mild-to-moderate. Most respondents (61.0%) took a biological. Median frequency of MC use was at least once within the past week. Most respondents used products with high Δ9-tetrahydrocannabinol content (87.5%) through vape pens/cartridges (78.6%). Respondents reported fewer emergency room visits in the 12 months after versus before MC use (35.2 vs 41.5%, P <0.01) and less impact of symptoms on daily life. Most respondents reported euphoria with MC use (75.4%). The other common side effects were feeling drowsy, groggy, or with memory lapses (4.2%), dry mouth/eyes (3.4%), and anxiety/depression or paranoia (3.4%). Few respondents reported MC diversion (1.3%).
    Conclusions: MC users with IBD perceive symptom benefits and report decreased emergency room visits without serious adverse effects. Further studies are needed to confirm these results with objective measures of healthcare utilization and disease activity.
    MeSH term(s) Humans ; Adolescent ; Medical Marijuana/adverse effects ; Cross-Sectional Studies ; Inflammatory Bowel Diseases/drug therapy ; Depression ; Surveys and Questionnaires
    Chemical Substances Medical Marijuana
    Language English
    Publishing date 2023-09-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 448460-5
    ISSN 1539-2031 ; 0192-0790
    ISSN (online) 1539-2031
    ISSN 0192-0790
    DOI 10.1097/MCG.0000000000001782
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Editorial: older patients are significantly more likely to have colon ischaemia-associated conditions that are chronic and complex-authors' reply.

    Silverman, Michael / Aroniadis, Olga C / Feuerstadt, Paul / Brandt, Lawrence J

    Alimentary pharmacology & therapeutics

    2019  Volume 50, Issue 3, Page(s) 330

    MeSH term(s) Colon ; Hepatitis B, Chronic ; Humans
    Language English
    Publishing date 2019-07-17
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.15369
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis.

    Halkjær, Sofie Ingdam / Lo, Bobby / Cold, Frederik / Højer Christensen, Alice / Holster, Savanne / König, Julia / Brummer, Robert Jan / Aroniadis, Olga C / Lahtinen, Perttu / Holvoet, Tom / Gluud, Lise Lotte / Petersen, Andreas Munk

    World journal of gastroenterology

    2023  Volume 29, Issue 20, Page(s) 3185–3202

    Abstract: Background: Irritable bowel syndrome (IBS) is the most prevalent gastrointestinal disorder in developed countries and reduces patients' quality of life, hinders their ability to work, and increases health care costs. A growing number of trials have ... ...

    Abstract Background: Irritable bowel syndrome (IBS) is the most prevalent gastrointestinal disorder in developed countries and reduces patients' quality of life, hinders their ability to work, and increases health care costs. A growing number of trials have demonstrated an aberrant gut microbiota composition in IBS, also known as 'gut dysbiosis'. Fecal microbiota transplantation (FMT) has been suggested as a treatment for IBS.
    Aim: To assess the efficacy and safety of FMT for the treatment of IBS.
    Methods: We searched Cochrane Central, MEDLINE, EMBASE and Web of Science up to 24 October 2022 for randomised controlled trials (RCTs) investigating the effectiveness of FMT compared to placebo (including autologous FMT) in treating IBS. The primary outcome was the number of patients with improvements of symptoms measured using a validated, global IBS symptoms score. Secondary outcomes were changes in quality-of-life scores, non-serious and serious adverse events. Risk ratios (RR) and corresponding 95%CI were calculated for dichotomous outcomes, as were the mean differences (MD) and 95%CI for continuous outcomes. The Cochrane risk of bias tool was used to assess the quality of the trials. GRADE criteria were used to assess the overall quality of the evidence.
    Results: Eight RCTs (484 participants) were included in the review. FMT resulted in no significant benefit in IBS symptoms three months after treatment compared to placebo (RR 1.19, 95%CI: 0.68-2.10). Adverse events were reported in 97 participants in the FMT group and in 45 participants in the placebo group (RR 1.17, 95%CI: 0.63-2.15). One serious adverse event occurred in the FMT group and two in the placebo group (RR 0.42, 95%CI: 0.07-2.60). Endoscopic FMT delivery resulted in a significant improvement in symptoms, while capsules did not. FMT did not improve the quality of life of IBS patients but, instead, appeared to reduce it, albeit non significantly (MD -6.30, 95%CI: -13.39-0.79). The overall quality of the evidence was low due to moderate-high inconsistency, the small number of patients in the studies, and imprecision.
    Conclusion: We found insufficient evidence to support or refute the use of FMT for IBS. Larger trials are needed.
    MeSH term(s) Humans ; Irritable Bowel Syndrome/therapy ; Irritable Bowel Syndrome/etiology ; Fecal Microbiota Transplantation/adverse effects ; Fecal Microbiota Transplantation/methods ; Gastrointestinal Microbiome ; Quality of Life ; Dysbiosis/therapy ; Dysbiosis/etiology
    Language English
    Publishing date 2023-06-06
    Publishing country United States
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v29.i20.3185
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease.

    Aroniadis, Olga C / Brandt, Lawrence J

    Gastroenterology & hepatology

    2014  Volume 10, Issue 4, Page(s) 230–237

    Abstract: Fecal microbiota transplantation (FMT) refers to the infusion of a fecal suspension from a healthy person into the gastrointestinal (GI) tract of another person to cure a specific disease. FMT is by no means a new therapeutic modality, although it was ... ...

    Abstract Fecal microbiota transplantation (FMT) refers to the infusion of a fecal suspension from a healthy person into the gastrointestinal (GI) tract of another person to cure a specific disease. FMT is by no means a new therapeutic modality, although it was only relatively recently that stool was shown to be a biologically active, complex mixture of living organisms with great therapeutic potential for recurrent Clostridium difficile infection and perhaps other GI and non-GI disorders. The published revelations about the human microbiome are bringing the strength of science to clinical observation and enhancing the understanding of not only disease but also how much of a person's daily function and health depends on the microorganisms living in intimate relationship with each cell in the body.
    Language English
    Publishing date 2014-06-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: A Perspective on Brain-Gut Communication: The American Gastroenterology Association and American Psychosomatic Society Joint Symposium on Brain-Gut Interactions and the Intestinal Microenvironment.

    Aroniadis, Olga C / Drossman, Douglas A / Simrén, Magnus

    Psychosomatic medicine

    2017  Volume 79, Issue 8, Page(s) 847–856

    Abstract: Background: Alterations in brain-gut communication and the intestinal microenvironment have been implicated in a variety of medical and neuropsychiatric diseases. Three central areas require basic and clinical research: (1) how the intestinal ... ...

    Abstract Background: Alterations in brain-gut communication and the intestinal microenvironment have been implicated in a variety of medical and neuropsychiatric diseases. Three central areas require basic and clinical research: (1) how the intestinal microenvironment interacts with the host immune system, central nervous system, and enteric nervous system; (2) the role of the intestinal microenvironment in the pathogenesis of medical and neuropsychiatric disease; and (3) the effects of diet, prebiotics, probiotics, and fecal microbiota transplantation on the intestinal microenvironment and the treatment of disease.
    Methods: This review article is based on a symposium convened by the American Gastroenterology Association and the American Psychosomatic Society to foster interest in the role of the intestinal microenvironment in brain-gut communication and pathogenesis of neuropsychiatric and biopsychosocial disorders. The aims were to define the state of the art of the current scientific knowledge base and to identify guidelines and future directions for new research in this area.
    Results: This review provides a characterization of the intestinal microbial composition and function. We also provide evidence for the interactions between the intestinal microbiome, the host, and the environment. The role of the intestinal microbiome in medical and neuropsychiatric diseases is reviewed as well as the treatment effects of manipulation of the intestinal microbiome.
    Conclusions: Based on this review, opportunities and challenges for conducting research in the field are described, leading to potential avenues for future research.
    Language English
    Publishing date 2017-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3469-1
    ISSN 1534-7796 ; 0033-3174
    ISSN (online) 1534-7796
    ISSN 0033-3174
    DOI 10.1097/PSY.0000000000000431
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: An overview of fecal microbiota transplantation: techniques, indications, and outcomes.

    Brandt, Lawrence J / Aroniadis, Olga C

    Gastrointestinal endoscopy

    2013  Volume 78, Issue 2, Page(s) 240–249

    MeSH term(s) Clostridium difficile ; Enterocolitis, Pseudomembranous/therapy ; Feces/microbiology ; Humans ; Inflammatory Bowel Diseases/therapy ; Irritable Bowel Syndrome/therapy ; Microbiota ; Patient Selection ; Recurrence ; Transplantation/methods
    Language English
    Publishing date 2013-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 391583-9
    ISSN 1097-6779 ; 0016-5107
    ISSN (online) 1097-6779
    ISSN 0016-5107
    DOI 10.1016/j.gie.2013.03.1329
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection.

    Feuerstadt, Paul / Aroniadis, Olga C / Svedlund, Felicia L / Garcia, Mariana / Stong, Laura / Boules, Mena / Khanna, Sahil

    Digestive diseases and sciences

    2021  Volume 67, Issue 7, Page(s) 2763–2770

    Abstract: Introduction: Clinical trials have demonstrated the efficacy of FMT for reduction in CDI recurrences (rCDI), but this treatment and its reporting in the literature has significant heterogeneity. Recent publications (e.g., Ramai et al. in Dig Dis Sci ... ...

    Abstract Introduction: Clinical trials have demonstrated the efficacy of FMT for reduction in CDI recurrences (rCDI), but this treatment and its reporting in the literature has significant heterogeneity. Recent publications (e.g., Ramai et al. in Dig Dis Sci 2020. https://doi.org/10.1007/s10620-020-06185-7 ) present the clinical outcomes for different FMT methodologies. However, to understand, compare, and contextualize outcomes, this heterogeneity in methods and reporting must be understood.
    Methods: We performed a literature review of randomized controlled trials (RCTs) of FMT for rCDI to evaluate heterogeneity among trials. A methodical search between January 2010 and May 2019 of Medline, Embase, and Cochrane was conducted for studies investigating FMT in adults with rCDI. RCTs were evaluated for a variety of methodological and reporting criteria.
    Results: Eight RCTs were identified, wherein 14 different FMT preparations were considered (each with distinct protocols for processing, storage, administration, and dosing). Sample sizes were generally small, with only two studies performing FMT in more than 100 patients. Three studies used non-FMT controls (vancomycin), while the remaining compared FMT with differing routes of administration or formulations. Across the identified studies, there was no standardized manner for reporting the timing of the FMT procedure. All studies tracked adverse events; however, follow-up periods were limited.
    Conclusions: Considerable variability exists among RCTs, with marked differences in study design, control groups, and outcome assessment. Lack of a standard-of-care control in many trials may impact reproducibility of FMT trial outcomes in patients with rCDI. Widespread use of FMT for rCDI is still investigational; therefore, these foundational studies provide opportunities to optimize future trials.
    MeSH term(s) Adult ; Clostridioides difficile ; Clostridium Infections/drug therapy ; Fecal Microbiota Transplantation/adverse effects ; Fecal Microbiota Transplantation/methods ; Humans ; Randomized Controlled Trials as Topic ; Recurrence ; Treatment Outcome
    Language English
    Publishing date 2021-07-18
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 304250-9
    ISSN 1573-2568 ; 0163-2116
    ISSN (online) 1573-2568
    ISSN 0163-2116
    DOI 10.1007/s10620-021-07141-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Factors Associated with the Development of Gastrointestinal Symptoms in Patients Hospitalized with Covid-19.

    Aroniadis, Olga C / Wang, Xianling / Gong, Tang / Forbes, Nauzer / Yang, Jeong Yun / Canakis, Andrew / Elmunzer, Badih Joseph / Yadav, Dhiraj

    Digestive diseases and sciences

    2021  Volume 67, Issue 8, Page(s) 3860–3871

    Abstract: Background and aims: The most common symptoms of Covid-19 are respiratory; however, gastrointestinal symptoms are present in up to 50% of patients. We aimed to determine characteristics associated with the development of gastrointestinal symptoms in ... ...

    Abstract Background and aims: The most common symptoms of Covid-19 are respiratory; however, gastrointestinal symptoms are present in up to 50% of patients. We aimed to determine characteristics associated with the development of gastrointestinal symptoms in patients with Covid-19.
    Methods: A case-control study of adults hospitalized for Covid-19 was conducted across a geographically diverse alliance of 36 US and Canadian medical centers. Data were manually abstracted from electronic health records and analyzed using regression analyses to determine characteristics associated with any gastrointestinal symptoms and diarrhea specifically.
    Results: Of 1406 patients, 540 (38%) reported at least one gastrointestinal symptom and 346 (25%) reported diarrhea. Older patients (≥ 80 years) had significantly lower rates of any gastrointestinal symptoms and diarrhea (vs. patients 18-79 years, OR 0.41, p < 0.01 and OR 0.43 p = 0.01, respectively), while those with IBS (OR 7.70, p = 0.02 and OR 6.72, p < 0.01, respectively) and on immunosuppressive therapy (OR = 1.56, p = 0.02) had higher rates of any gastrointestinal symptom and diarrhea. Patients with constitutional symptoms exhibited significantly higher rates (OR 1.91, p < 0.01), while those with pulmonary disease alone had lower rates of gastrointestinal symptoms (OR 0.23, p = 0.01). A significant interaction between constitutional symptoms and pre-existing pulmonary conditions was observed.
    Conclusions: Several patient- and disease-specific characteristics associate with gastrointestinal symptoms in patients with Covid-19. Knowledge of these may provide insights into associated pathophysiologic mechanisms, and help health care professionals provide targeted attention to reduce morbidity related to Covid-19.
    MeSH term(s) Adult ; COVID-19/complications ; Canada ; Case-Control Studies ; Diarrhea/epidemiology ; Diarrhea/etiology ; Gastrointestinal Diseases/diagnosis ; Gastrointestinal Diseases/epidemiology ; Gastrointestinal Diseases/etiology ; Humans ; SARS-CoV-2
    Language English
    Publishing date 2021-11-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 304250-9
    ISSN 1573-2568 ; 0163-2116
    ISSN (online) 1573-2568
    ISSN 0163-2116
    DOI 10.1007/s10620-021-07286-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Outcomes of COVID-19 Among Hospitalized Health Care Workers in North America.

    Yang, Jeong Yun / Parkins, Michael D / Canakis, Andrew / Aroniadis, Olga C / Yadav, Dhiraj / Dixon, Rebekah E / Elmunzer, B Joseph / Forbes, Nauzer

    JAMA network open

    2021  Volume 4, Issue 1, Page(s) e2035699

    Abstract: Importance: Although health care workers (HCWs) are at higher risk of acquiring coronavirus disease 2019 (COVID-19), it is unclear whether they are at risk of poorer outcomes.: Objective: To evaluate the association between HCW status and outcomes ... ...

    Abstract Importance: Although health care workers (HCWs) are at higher risk of acquiring coronavirus disease 2019 (COVID-19), it is unclear whether they are at risk of poorer outcomes.
    Objective: To evaluate the association between HCW status and outcomes among patients hospitalized with COVID-19.
    Design, setting, and participants: This retrospective, observational cohort study included consecutive adult patients hospitalized with a diagnosis of laboratory-confirmed COVID-19 across 36 North American centers from April 15 to June 5, 2020. Data were collected from 1992 patients. Data were analyzed from September 10 to October 1, 2020.
    Exposures: Data on patient baseline characteristics, comorbidities, presenting symptoms, treatments, and outcomes were collected, including HCW status.
    Main outcomes and measures: The primary outcome was a requirement for mechanical ventilation or death. Multivariable logistic regression was performed to yield adjusted odds ratios (AORs) and 95% CIs for the association between HCW status and COVID-19-related outcomes in a 3:1 propensity score-matched cohort, adjusting for residual confounding after matching.
    Results: In total, 1790 patients were included, comprising 127 HCWs and 1663 non-HCWs. After 3:1 propensity score matching, 122 HCWs were matched to 366 non-HCWs. Women comprised 71 (58.2%) of matched HCWs and 214 (58.5%) of matched non-HCWs. Matched HCWs had a mean (SD) age of 52 (13) years, whereas matched non-HCWs had a mean (SD) age of 57 (17) years. In the matched cohort, the odds of the primary outcome, mechanical ventilation or death, were not significantly different for HCWs compared with non-HCWs (AOR, 0.60; 95% CI, 0.34-1.04). The HCWs were less likely to require admission to an intensive care unit (AOR, 0.56; 95% CI, 0.34-0.92) and were also less likely to require an admission of 7 days or longer (AOR, 0.53; 95% CI, 0.34-0.83). There were no differences between matched HCWs and non-HCWs in terms of mechanical ventilation (AOR, 0.66; 95% CI, 0.37-1.17), death (AOR, 0.47; 95% CI, 0.18-1.27), or vasopressor requirements (AOR, 0.68; 95% CI, 0.37-1.24).
    Conclusions and relevance: In this propensity score-matched multicenter cohort study, HCW status was not associated with poorer outcomes among hospitalized patients with COVID-19 and, in fact, was associated with a shorter length of hospitalization and decreased likelihood of intensive care unit admission. Further research is needed to elucidate the proportion of HCW infections acquired in the workplace and to assess whether HCW type is associated with outcomes.
    MeSH term(s) Adult ; Aged ; COVID-19/etiology ; COVID-19/mortality ; COVID-19/therapy ; Comorbidity ; Female ; Health Personnel ; Hospitalization ; Humans ; Intensive Care Units ; Length of Stay ; Male ; Middle Aged ; North America ; Occupational Exposure ; Odds Ratio ; Respiration, Artificial ; Retrospective Studies ; SARS-CoV-2 ; Severity of Illness Index ; Vasoconstrictor Agents/therapeutic use ; Workplace
    Chemical Substances Vasoconstrictor Agents
    Language English
    Publishing date 2021-01-04
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Observational Study
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2020.35699
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top